CC
BIIB icon

Callan Capital’s Biogen BIIB Stock Holding History

Callan Capital’s Portfolio BIIB Stock Details BIIB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		$292K Buy
2,131
+56
+3% +$8.01K 0.02% 290
2024
Q4 		$317K Buy
2,075
+970
+88% +$164K 0.02% 247
2024
Q3 		$214K Sell
1,105
-2,116
-66% -$443K 0.02% 322
2024
Q2 		$747K Buy
3,221
+180
+6% +$39.1K 0.06% 129
2024
Q1 		$656K Buy
3,041
+223
+8% +$52.2K 0.06% 124
2023
Q4 		$729K Buy
2,818
+329
+13% +$80.8K 0.07% 106
2023
Q3 		$640K Sell
2,489
-151
-6% -$40.4K 0.07% 100
2023
Q2 		$752K Hold
2,640
– – 0.08% 89
2023
Q1 		$734K Hold
2,640
– – 0.09% 89
2022
Q4 		$731K Buy
+2,640
New +$746K 0.09% 93
2016
Q3 		– Sell
-3,644
Closed -$881K – 50
2016
Q2 		$881K Sell
3,644
-552
-13% -$145K 0.36% 30
2016
Q1 		$1.09M Hold
4,196
– – 0.46% 26
2015
Q4 		$1.28M Sell
4,196
-330
-7% -$94.8K 0.51% 27
2015
Q3 		$1.32M Hold
4,526
– – 0.72% 24
2015
Q2 		$1.83M Hold
4,526
– – 0.38% 29
2015
Q1 		$1.91M Hold
4,526
– – 0.41% 29
2014
Q4 		$1.54M Hold
4,526
– – 0.35% 36
2014
Q3 		$1.5M Sell
4,526
-760
-14% -$251K 0.41% 34
2014
Q2 		$1.67M Sell
5,286
-130
-2% -$39.1K 0.45% 33
2014
Q1 		$1.66M Hold
5,416
– – 0.55% 26
2013
Q4 		$1.51M Hold
5,416
– – 0.58% 27
2013
Q3 		$1.3M Buy
5,416
+184
+4% +$41.2K 0.62% 26
2013
Q2 		$1.13M Buy
+5,232
New +$1.12M 0.64% 26

Other funds holding BIIB

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Callan Capital's BIIB Position: Q1 2025 in Review

Callan Capital increased its Biogen (BIIB) stake by 2.7% in Q1 2025, buying an estimated $8.01K and bringing the position to 2,131 shares worth $292K. The position accounts for 0.02% of the portfolio, ranked #290.

Callan Capital first reported a position in BIIB in Q2 2013 and has held it in 23 quarters since. The position peaked at $1.91M in Q1 2015. 882 funds tracked by Wall St. Rank hold BIIB as of Q1 2025.

  • Callan Capital held 2,131 shares of Biogen worth $292K as of Q1 2025.
  • Callan Capital bought 56 Biogen shares in Q1 2025, an estimated $8.01K.
  • Biogen made up 0.02% of Callan Capital's portfolio in Q1 2025, its #290 holding.
  • Callan Capital first reported a position in Biogen in Q2 2013 and has held it in 23 quarters since.
  • Callan Capital's Biogen position peaked at $1.91M in Q1 2015.
  • 882 funds tracked by Wall St. Rank held Biogen as of Q1 2025.

Based on Callan Capital's 13F filing for Q1 2025, filed 29 Apr 2025.